Core Points - Mural Oncology plc's shareholders approved the acquisition by XRA 5 Corp, a subsidiary of XOMA Royalty Corporation, with over 99% of votes in favor at both the Scheme Meeting and Extraordinary General Meeting held on October 24, 2025 [1][4][10] Acquisition Details - The acquisition agreement stipulates that Mural shareholders will receive a base cash price of $2.035 per share, based on an estimated closing net cash of approximately $36.2 million [2][3] - The total value of Mural's issued share capital is approximately $36.2 million, excluding any additional cash that may be payable [3] - The acquisition is expected to close in the fourth quarter of 2025, pending customary closing conditions and approval from the High Court of Ireland [3] Voting Results - At the Scheme Meeting, 10,103,706 shares (99.20%) voted in favor of the proposal, representing 58.31% of the total shares outstanding [8][9] - At the EGM, 10,607,228 shares (99.16%) approved the proposal, with 10,647,967 shares (99.54%) voting in favor of the amendment to the articles of association [10][10]

Core Insights - Genmab, a Denmark-based biotech company, announced a significant acquisition of Merus for $8 billion, paying $97 per share in cash, which has been positively received by analysts and the market [2][3] Group 1: Acquisition Details - The acquisition of Merus is expected to close in the first calendar quarter of 2026 and is seen as a strategic move to accelerate Genmab's transition to a wholly owned model, diversifying revenue and driving growth [2][3] - Analysts view the acquisition as beneficial, particularly highlighting the attractive price for Merus's late-stage cancer drug, petosemtamab [3] Group 2: Analyst Reactions - Truist Securities analyst Asthika Goonewardene reiterated a buy recommendation for Genmab with a price target of $46 per share [3] - TD Cowen's Yaron Werber raised his price target for Genmab from $24 to $32 per share, maintaining a hold recommendation, indicating a more cautious outlook [4] Group 3: Market Performance - Following the acquisition announcement, Genmab's stock rose nearly 5%, significantly outperforming the S&P 500, which only saw a marginal increase of 0.1% [1]

Core Insights - Genmab has agreed to acquire all shares of Merus for $97 per share, totaling $8 billion, enhancing its oncology pipeline [1][4] - The acquisition is supported by both companies' boards and is expected to transition Genmab to a fully owned business model [1][2] - The deal is projected to close in early Q1 2026, with a key asset being Merus' petosemtamab, currently in Phase III development [2][3] Financial Details - The acquisition price represents a 41% premium over Merus' closing stock price on September 26, 2025, and a 44% premium over the 30-day volume-weighted average price of $67.42 [4] - Genmab plans to finance the acquisition through existing cash and $5.5 billion in non-convertible debt, with backing from Morgan Stanley Senior Funding [4] Strategic Implications - The acquisition aligns with Genmab's long-term strategy to become a global biotechnology leader, providing sustainable growth into the next decade [6] - Petosemtamab is expected to be a transformative therapy for head and neck cancer, with potential launch in 2027 depending on clinical outcomes and regulatory approvals [3][6] Advisory Information - Genmab is advised by PJT Partners and Morgan Stanley & Co International, with legal counsel from A&O Shearman and Kromann Reumert [5] - Merus is advised by Jefferies, with legal counsel from Latham & Watkins and NautaDutilh [5]

Core Viewpoint - BioMarin Pharmaceutical Inc. has successfully completed the acquisition of Inozyme Pharma, Inc. for $4.00 per share in an all-cash transaction valued at approximately $270 million, enhancing BioMarin's enzyme therapies portfolio with the addition of late-stage therapy INZ-701 for ENPP1 Deficiency [1][2][3] Group 1: Acquisition Details - The acquisition agreement was initially announced on May 16, 2025, with a tender offer commencing on June 2, 2025, to acquire all outstanding shares of Inozyme at $4.00 per share [2] - The tender offer expired on June 30, 2025, with 45,455,118 shares validly tendered, representing about 70% of the total shares [3] - Following the merger, all remaining shares not tendered were converted into the right to receive $4.00 per share in cash, and the shares ceased trading on the Nasdaq Global Select Market [3] Group 2: Company Profiles - BioMarin is a global biotechnology company focused on developing medicines from genetic discoveries, with a strong pipeline and eight commercial therapies [5] - Inozyme Pharma is a clinical-stage biopharmaceutical company with a focus on therapeutics targeting the PPi-Adenosine Pathway, particularly for conditions like ENPP1 Deficiency [6]